Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATACAND HCT vs PHYSIOSOL IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
PHYSIOSOL is a sterile, non-pyrogenic isotonic solution of electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate, and gluconate) in water for injection. It serves as a source of water and electrolytes to expand extracellular fluid volume and maintain osmotic balance. The acetate and gluconate ions are metabolized to bicarbonate, providing an alkalinizing effect.
Treatment of hypertension, for patients not adequately controlled on monotherapy.
Intravenous solution for fluid and electrolyte replacement in patients with isotonic or hypotonic dehydration,Maintenance of fluid and electrolyte balance during surgery or in postoperative patients,Vehicle for administration of compatible medications
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Intravenous infusion; dose based on fluid and electrolyte requirements; typical adult dose: 500-1000 m L/h as needed to maintain hydration and electrolyte balance.
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Not applicable (physiologic solution); infused electrolytes and water distribute and are eliminated with kinetics dependent on renal function; terminal half-life reflects water turnover (~3-6 days in healthy adults).
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
The acetate and gluconate ions are metabolized in the liver and peripheral tissues, primarily via the tricarboxylic acid cycle, to bicarbonate. Electrolytes (sodium, potassium, calcium, magnesium, chloride) are not metabolized but are excreted or reabsorbed as per physiological needs.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal excretion of water and electrolytes; >95% of administered volume is excreted unchanged by kidneys within 24 hours; minimal (<5%) fecal or biliary elimination.
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Negligible (<1%); electrolytes are not bound to plasma proteins.
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Approximately 0.55 L/kg (total body water); distributes into extracellular fluid (0.2 L/kg) and intracellular water (0.4 L/kg).
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
Intravenous: 100%; oral: 100% (but not relevant as product is for IV use only).
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
No dose adjustment required; monitor serum electrolytes and fluid balance closely in renal impairment; adjust infusion rate based on renal function to avoid fluid overload.
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
No specific dose adjustment required; monitor serum electrolytes and acid-base balance in severe hepatic impairment.
Safety and efficacy not established in pediatric patients (<18 years).
Intravenous infusion; dosing based on body weight; typical dose: 10-20 m L/kg for acute replacement, then adjust based on maintenance requirements; monitor electrolyte levels.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
Use with caution; start with lower end of dosing range; monitor for fluid overload, electrolyte disturbances, and renal function due to age-related changes.
None.
Not for injection into the epidural, intrathecal, or intra-arterial spaces. Do not administer if solution contains visible particulate matter or is discolored. Use only if solution is clear and container is undamaged.
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload,Avoid rapid administration to prevent hypervolemia and electrolyte disturbances,Contains potassium; use cautiously in patients with hyperkalemia or conditions predisposing to potassium retention,Contains calcium; do not administer simultaneously with blood products through the same IV line due to risk of precipitation
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
Hypersensitivity to any component of the solution,Hyperkalemia,Hypercalcemia,Severe metabolic alkalosis,Patients with significant fluid overload or pulmonary edema,Concomitant administration with blood products via same IV line
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
No specific food interactions. However, consider overall fluid and electrolyte intake from diet, especially sodium and potassium, to avoid imbalances.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
Physiosol in plastic container is a sterile, non-pyrogenic isotonic solution of electrolytes and water. It contains no known teratogenic agents. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this solution. Therefore, it should be used during pregnancy only if clearly needed. No specific fetal risks have been identified for any trimester when used as directed.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
Safety in breastfeeding has not been established. Since Physiosol is a balanced electrolyte solution, it is unlikely to pose significant risk to the nursing infant. However, caution is advised. The milk-to-plasma (M/P) ratio is not available.
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
No specific dosing adjustments are required for pregnancy based on pharmacokinetic changes. However, pregnant patients may have increased plasma volume, and fluid and electrolyte requirements should be individualized. Caution is advised in preeclampsia or conditions with fluid overload.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Physiosol in plastic container is a balanced electrolyte solution for intravenous administration, primarily used for replacement of extracellular fluid losses. Monitor for signs of fluid overload, especially in patients with heart failure or renal impairment. The plastic container may leach phthalates; use with caution in neonates and pregnant women. Do not administer if solution is discolored or contains particulate matter.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction, such as rash, itching, or difficulty breathing.,Notify your healthcare provider if you experience swelling, shortness of breath, or rapid weight gain.,Do not stop the infusion without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATACAND HCT vs PHYSIOSOL IN PLASTIC CONTAINER, answered by our medical review team.
ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. PHYSIOSOL IN PLASTIC CONTAINER is a Irrigation Solution that works by PHYSIOSOL is a sterile, non-pyrogenic isotonic solution of electrolytes (sodium, potassium, calcium, magnesium, chloride, acetate, and gluconate) in water for injection. It serves as a source of water and electrolytes to expand extracellular fluid volume and maintain osmotic balance. The acetate and gluconate ions are metabolized to bicarbonate, providing an alkalinizing effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATACAND HCT and PHYSIOSOL IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. The standard adult dose of PHYSIOSOL IN PLASTIC CONTAINER is: Intravenous infusion; dose based on fluid and electrolyte requirements; typical adult dose: 500-1000 m L/h as needed to maintain hydration and electrolyte balance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATACAND HCT and PHYSIOSOL IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. PHYSIOSOL IN PLASTIC CONTAINER is classified as Category C. Physiosol in plastic container is a sterile, non-pyrogenic isotonic solution of electrolytes and water. It contains no known teratogenic agents. There are no adequate and well-cont. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.